Référentiel des médicaments
Pralsetinib
Pralsetinib is a medicine in the class oncology. It is used for non-small cell lung cancer.
- Classe médicamenteuse: Oncology
- Indications: non-small cell lung cancer
Dernière mise à jour Sources: US FDA label
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Oncology
- Formes courantes
- gélule
- Dosages courants
- 100 mg
- Interactions connues
- 16 (Majeure: 15 · Modérée: 1)
- Noms commerciaux
- 1
- Pays et marchés
- 1
Indications
Mécanisme d'action
Kinase inhibitor of wild-type RET and oncogenic RET fusions and mutations (IC50s less than 0.5 nM); inhibits downstream signaling that drives uncontrolled cell proliferation.
Posologie adulte habituelle (résumé de la notice)
RET fusion-positive NSCLC or thyroid cancer: 400 mg orally once daily on an empty stomach (no food for at least 2 hours before and at least 1 hour after); continue until disease progression or unacceptable toxicity
Grossesse et allaitement
- Grossesse
- Unsafe Can cause fetal harm: in rats it caused malformations and embryo death below human exposure; no human data. Avoid in pregnancy; check pregnancy status. Women: non-hormonal contraception during treatment and for 2 weeks after (it may make hormonal methods fail); men: 1 week.
- Allaitement
- Unsafe No data on passage into milk; it is 97% protein bound, but its 22-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose.
Effets indésirables signalés
- Musculoskeletal pain
- Constipation
- Hypertension
- Diarrhea
- Fatigue
- Edema
Mises en garde encadrées
- May increase the risk of serious bacterial, fungal, viral and opportunistic infections, which can lead to hospitalization or death. Withhold, reduce the dose or permanently discontinue based on severity.
Précautions particulières
- Serious infections, including opportunistic and fatal infections: monitor for signs and symptoms and treat appropriately.
- Interstitial lung disease/pneumonitis can be severe, life-threatening or fatal; withhold and investigate for acute or worsening respiratory symptoms.
- Hypertension: do not initiate in uncontrolled hypertension; monitor BP after 1 week and at least monthly thereafter.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (16)
- Amobarbital + Pralsetinib Major
- Apalutamide + Pralsetinib Major
- Carbamazepine + Pralsetinib Major
- Chloramphenicol + Pralsetinib Major
- Clarithromycin + Pralsetinib Major
- Efavirenz + Pralsetinib Major
- Enzalutamide + Pralsetinib Major
- Itraconazole + Pralsetinib Major
- Ketoconazole + Pralsetinib Major
- Lorlatinib + Pralsetinib Major
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Pralsetinib : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Pralsetinib used for?
Pralsetinib is a medicine in the class oncology. It is used for Non-small cell lung cancer, Thyroid cancer.
What side effects have been reported with Pralsetinib?
Musculoskeletal pain, Constipation, Hypertension, Diarrhea, Fatigue, Edema. Serious warning: May increase the risk of serious bacterial, fungal, viral and opportunistic infections, which can lead to hospitalization or death.
Can Pralsetinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: in rats it caused malformations and embryo death below human exposure; no human data. Avoid in pregnancy; check pregnancy status. Women: non-hormonal contraception during treatment and for 2 weeks after (it may make hormonal methods fail); men: 1 week. Breastfeeding: Unsafe. No data on passage into milk; it is 97% protein bound, but its 22-hour half-life may allow build-up in the infant (LactMed). Do not breastfeed during treatment and for 1 week after the last dose.
What does Pralsetinib interact with?
MediHelp lists 16 known interactions for Pralsetinib. Major: 15 · Moderate: 1. The most serious include Amobarbital, Apalutamide, Carbamazepine.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
